EMEA-001612-PIP01-14

Key facts

Invented name
Transvax
Active substance
Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes (ASP0113)
Therapeutic area
Infectious diseases
Decision number
P/0338/2014
PIP number
EMEA-001612-PIP01-14
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of cytomegalovirus disease in patients with impaired cell-mediated immunity
Route(s) of administration
Intramuscular use
Contact for public enquiries
Astellas Pharma Europe B.V. 
The Netherlands 
E-mail: contact@nl.astellas.com 
Tel. +31 715455878 
Fax +31 715455224
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating